EFTA02694296.pdf

DIRECTORS, OFFICERS, FOUNDERS AND ADVISORS Board of Directors: Kapil Dhingra, M.D Drug development expert, former head ofRoche Oncology Leadership Team; led growth of oncology franchise from $800m to >$10 Billion per annum. Michael Gargano Managing Director of Argent Ventures, real estate developer and investor in major US cities, primarily New York, LA and Miami. Colin Goddard, Ph.D CEO of OSI Pharmaceuticals from 1998 until its $4B acquisition by Astellas Pharmaceuticals in June 2010; joined OSI as a scientist in 1989; presided over transition from $64M market cap to fully integrated biopharmaceutical company with $500M in revenue in 2010. Currently a director of Human Genome Sciences, Zelos and PanOptica. Alan Lewis, Ph.D. Chairman and CEO of Ambit Biosciences; previously President ofResearch at Celgene, CEO ofNovocell, CEO of Signal Therapeutics, and VP ofResearch at Wyeth. Viren Mehta 25+ year career advising biopharmaceutical industry worldwide: Founding Partner of Mehta Partners and earlier of Mehta & Islay; Management at Merck & Co.; Recently BOD at OS1Pharmaceuticals. Mark Simon Former head ofhealthcare investment banking CitiGroup, renown biotech financier, has raised more than $30 Billion in public and private financings and many global strategic partnerships, current industry advisor. Management: Colin Goddard, Ph.D CEO of OSI Pharmaceuticals from 1998 until its Executive Chairman $4B acquisition by Astellas Pharmaceuticals in June 2010; joined OSI as a scientist in 1989; presided over transition from $64M market cap to fully integrated biopharmaceutical company with $500M in revenue in 2010. Currently a director of Human Genome Sciences, Zelos and PanOptica. 22 USIDOCS7895963O EFTA_R1_02040903 EFTA02694296  Derek A. Small President of Luson Bioventures: focuses on starting Interim/ founding CEO, Director new biotech ventures, drug developer of multiple molecules to human studies, raised >$50m in start up financing; part of early or founding management at Semafore Pharmaceuticals, Simdesk, Kinagen, Endgenitor, Naurex, and other start ups Lee Arnold, PIED 22+ years in pharma discovery; former VP of US Chief Scientific Officer Research for OSI, inventor of Tarceva®, leading cancer drug >$1 Billion sales in 08, and 6 other molecules into clinical development; previously at Abbott, Pfizer. Jim Schulz Partner in Upward Focus, LLC; over 20 years of Head of Finance experience in public accounting, Fortune 500 and start-up companies; focus expertise in outsourced financial support for small biotech companies including SonarMed Inc., Tigas Pharmaceuticals, and Naurex Inc. Founding Scientists: Francis Barony, Ph.D. Professor at Weill Medical College of Cornell Founder, Chief Scientist University; Inventor on 34 issued patents including ligase chain reaction (LCR) and others generating >$1.3B sales; >110 publications; numerous awards including Scientific American Top 50 Scientists in 2004; Ph.D. from Rockefeller 1981 Donald Bergstrom, Ph.D. Walther Professor of Medicinal Chemistry at Purdue Founder, Chief Chemist University; 13 patents and >120 publications; numerous awards and advisor to several start-up biotechs; Chemistry Ph.D. from Berkley in 1970. Maneesh Pingle, Ph.D Instructor at Weill Medical College of Cornell Founder, Sr. Science Advisor University in the department of Microbiology; Ph.D. from Purdue University in Medicinal Chemistry and Molecular Pharmacology. 23 usiooamsvar.r EFTA_R1_02040904 EFTA02694297 Scientific Advisors: Paul Anderson, Ph.D Leading drug discovery expert, chemist, former head of discovery at, BMS and Merck/Dupont; awarded the ACS Priestley Medal, has discovered or developed several approved new drugs such as TRUSOPT, ZOCOR, CRIXIVAN and SUSTIVA that have achieved over $5 billion in aggregate annual sales. Homer L. Pearce, Ph.D Leading drug discovery expert, chemist, former head of oncology discovery & dev, Eli Lilly; awarded ACS Hero of Chemistry Award, has discovered or developed >25 clinical candidates and 3 FDA approved drugs with aggregate annual sales over $3 billion such as Gemzar, Alimta, and Oncotak. Charles Fisher, M.D. 35+ year career in clinical investigation and drug development: previously DVP, Global Pharmaceutical Development, Abbott Laboratories; Executive Director, Clinical Research Fellow, Eli Lilly (Xigris®); Professor and Head, Critical Care Medicine at the Cleveland Clinic Foundation Kama Dhingra, M.D Drug development expert, former head of Roche Oncology Leadership Team; led growth of oncology franchise from S800m to >$10 Billion per annum. 24 USIDOCS 7895963v3 EFTA_R1_02040905 EFTA02694298